323 related articles for article (PubMed ID: 20471514)
21. Bortezomib primes neuroblastoma cells for TRAIL-induced apoptosis by linking the death receptor to the mitochondrial pathway.
Naumann I; Kappler R; von Schweinitz D; Debatin KM; Fulda S
Clin Cancer Res; 2011 May; 17(10):3204-18. PubMed ID: 21459798
[TBL] [Abstract][Full Text] [Related]
22. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis.
Unterkircher T; Cristofanon S; Vellanki SH; Nonnenmacher L; Karpel-Massler G; Wirtz CR; Debatin KM; Fulda S
Clin Cancer Res; 2011 Jun; 17(12):4019-30. PubMed ID: 21525171
[TBL] [Abstract][Full Text] [Related]
23. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
Lashinger LM; Zhu K; Williams SA; Shrader M; Dinney CP; McConkey DJ
Cancer Res; 2005 Jun; 65(11):4902-8. PubMed ID: 15930312
[TBL] [Abstract][Full Text] [Related]
24. Effects of arsenic trioxide alone and in combination with bortezomib in multiple myeloma RPMI 8266 cells.
Elmahi AY; Niu C; Li W; Li D; Wang GJ; Hao SS; Cui JW
Asian Pac J Cancer Prev; 2013; 14(11):6469-73. PubMed ID: 24377552
[TBL] [Abstract][Full Text] [Related]
25. M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis.
Riccioni R; Senese M; Diverio D; Riti V; Buffolino S; Mariani G; Boe A; Cedrone M; Lo-Coco F; Foà R; Peschle C; Testa U
Br J Haematol; 2007 Oct; 139(2):194-205. PubMed ID: 17897295
[TBL] [Abstract][Full Text] [Related]
26. A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells.
Wang W; Adachi M; Zhang R; Zhou J; Zhu D
Pancreas; 2009 May; 38(4):e114-23. PubMed ID: 19342982
[TBL] [Abstract][Full Text] [Related]
27. Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-κB.
Bastian L; Hof J; Pfau M; Fichtner I; Eckert C; Henze G; Prada J; von Stackelberg A; Seeger K; Shalapour S
Clin Cancer Res; 2013 Mar; 19(6):1445-57. PubMed ID: 23357978
[TBL] [Abstract][Full Text] [Related]
28. Activation of the p38 MAPK/Akt/ERK1/2 signal pathways is required for the protein stabilization of CDC6 and cyclin D1 in low-dose arsenite-induced cell proliferation.
Liu Y; Hock JM; Sullivan C; Fang G; Cox AJ; Davis KT; Davis BH; Li X
J Cell Biochem; 2010 Dec; 111(6):1546-55. PubMed ID: 20862710
[TBL] [Abstract][Full Text] [Related]
29. Genistein synergizes with arsenic trioxide to suppress human hepatocellular carcinoma.
Jiang H; Ma Y; Chen X; Pan S; Sun B; Krissansen GW; Sun X
Cancer Sci; 2010 Apr; 101(4):975-83. PubMed ID: 20219070
[TBL] [Abstract][Full Text] [Related]
30. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling.
Chen X; Kandasamy K; Srivastava RK
Cancer Res; 2003 Mar; 63(5):1059-66. PubMed ID: 12615723
[TBL] [Abstract][Full Text] [Related]
31. [Apoptosis of myeloid leukemia cell line HL60 induced by Bortezomib, a proteasome inhibitor].
Fu YB; Sun QX; Meng FY; Xie J; Zhou GB
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(34):2413-6. PubMed ID: 17156654
[TBL] [Abstract][Full Text] [Related]
32. Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.
Denlinger CE; Rundall BK; Jones DR
J Thorac Cardiovasc Surg; 2004 Nov; 128(5):740-8. PubMed ID: 15514602
[TBL] [Abstract][Full Text] [Related]
33. Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2.
Smith MR; Jin F; Joshi I
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5528s-5534s. PubMed ID: 17875785
[TBL] [Abstract][Full Text] [Related]
34. Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta.
Yan H; Wang YC; Li D; Wang Y; Liu W; Wu YL; Chen GQ
Leukemia; 2007 Jul; 21(7):1488-95. PubMed ID: 17495969
[TBL] [Abstract][Full Text] [Related]
35. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
36. Cl-IB-MECA enhances TRAIL-induced apoptosis via the modulation of NF-kappaB signalling pathway in thyroid cancer cells.
Morello S; Sorrentino R; Porta A; Forte G; Popolo A; Petrella A; Pinto A
J Cell Physiol; 2009 Nov; 221(2):378-86. PubMed ID: 19562684
[TBL] [Abstract][Full Text] [Related]
37. Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP.
Kim YH; Jung EM; Lee TJ; Kim SH; Choi YH; Park JW; Park JW; Choi KS; Kwon TK
Free Radic Biol Med; 2008 Mar; 44(6):1055-68. PubMed ID: 18164688
[TBL] [Abstract][Full Text] [Related]
38. The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response.
Pagnan G; Di Paolo D; Carosio R; Pastorino F; Marimpietri D; Brignole C; Pezzolo A; Loi M; Galietta LJ; Piccardi F; Cilli M; Nico B; Ribatti D; Pistoia V; Ponzoni M
Clin Cancer Res; 2009 Feb; 15(4):1199-209. PubMed ID: 19228726
[TBL] [Abstract][Full Text] [Related]
39. Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin.
Jin HO; Yoon SI; Seo SK; Lee HC; Woo SH; Yoo DH; Lee SJ; Choe TB; An S; Kwon TJ; Kim JI; Park MJ; Hong SI; Park IC; Rhee CH
Biochem Pharmacol; 2006 Nov; 72(10):1228-36. PubMed ID: 16950207
[TBL] [Abstract][Full Text] [Related]
40. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells.
Sun SY; Yue P; Hong WK; Lotan R
Cancer Res; 2000 Dec; 60(24):7149-55. PubMed ID: 11156424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]